NUTRITIONAL-STATUS, GASTROINTESTINAL DYSFUNCTION, AND SURVIVAL IN PATIENTS WITH AIDS
- 1 October 1989
- journal article
- research article
- Vol. 84 (10) , 1288-1293
Abstract
The clinical course of 71 patients with acquired immune deficiency syndrome (AIDS) was evaluated to determine relationships among nutritional status, gastrointestinal symptoms and survival. At baseline, weight loss was present in 98%, hypoalbuminemia (< 3.5 g/dl) was present in 83%, and gastrointestinal symptoms included pharyngitis (54%), diarrhea (42%), nausea (23%), dysphagia (21%), and anorexia (18%). Both the magnitude of body weight loss and the serum albumin level were strongly associated with life-table analysis of survival. For weight loss, median survival of 520 vs. 48 days occurred in patients with < 10% versus > 20% baseline weight loss, respectively (p < 0.01). In almost all cases, serial evaluation demonstrated progressive linear decrease in body weight and albumin. In patients with normal baseline albumin, the rate of 0.7 mg/dl albumin decrease per day was less than half that in patients with baseline hypoalbuminemia. A projected "time to develop an albumin level < 2.5 g/dl" was calculated for patient groups based on initial albumin level and the rate of albumin decrease. The calculated interval was similar to the actual median survival time observed in these groups. We conclude that 1) nutritional status may represent a major determinant of survival in AIDS and 2) the rate of albumin decrease may define a function limiting survival of individual patients with AIDS.This publication has 16 references indexed in Scilit:
- Developmental Therapeutics and the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1987
- Length of survival of patients with acquired immune deficiency syndrome in the United Kingdom.BMJ, 1986
- Body composition studies in patients with the acquired immunodeficiency syndromeThe American Journal of Clinical Nutrition, 1985
- 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro.Proceedings of the National Academy of Sciences, 1985
- SLIM DISEASE: A NEW DISEASE IN UGANDA AND ITS ASSOCIATION WITH HTLV-III INFECTIONThe Lancet, 1985
- Malabsorption and Mucosal Abnormalities of the Small Intestine in the Acquired Immunodeficiency SyndromeAnnals of Internal Medicine, 1985
- GASTROINTESTINAL MANIFESTATIONS OF THE ACQUIRED IMMUNODEFICIENCY SYNDROME - A REVIEW OF 22 CASES1985
- Prognostic effect of weight loss prior tochemotherapy in cancer patientsThe American Journal of Medicine, 1980
- IMMUNOPARESIS AND OUTCOME IN MEASLESThe Lancet, 1977
- Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examplesBritish Journal of Cancer, 1977